Axil Capital's Past News
We moved to our new office in Minato-ku, Nishi-shimbashi.
Our portfolio company, Perseus Proteomics (4882), successfully completed its IPO listing on the Tokyo Stock Exchange Mothers Board.
Portfolio Companies' Past News
United Immunity completed Series B round.
United Immunity has entered into a joint research agreement with Xyphos/Astellas on cancer immunotherapy program.
United Immunity completed Series A2 round.
AIBIOS is working on three active programs to resolve unmet medical needs.
© Axil Capital All Rights Reserved
